Company Profile

TargaGenix Inc
Profile last edited on: 1/29/2024      CAGE: 76GC1      UEI: GZKVUPMHUBF3

Business Identifier: Novel cancer therapies targeting cancer stem cells
Year Founded
2013
First Award
2015
Latest Award
2016
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

25 Health Sciences Drive Suite 208
Stony Brook, NY 11790
   (516) 449-8148
   N/A
   www.targagenix.com
Location: Single
Congr. District: 01
County: Suffolk

Public Profile

Targeting cancer stem cells and bulk tumor cells, TargaGenix, Inc. is developing a novel therapy for treatment of cancer: novel compounds that are effective on both drug-resistant tumors and cancer stem cells. The firm's product - DHA-SBT-1214 - came out of a 10+ year effort to discover new molecules that were effective against chemotherapy resistant tumors and has been shown in preclinical models that it can treat and cure animals with tumor types that are resistant to current chemotherapy treatments. Work undertaken by the firm has shown that SBT-1214 is able to effectively down-regulate “stemness” gene expression and kill cancer stem cells. Additional chemical modifications and a novel fatty-acid based nanoemulsion formulation result in a drug that has improved pharmacokinetics and pharmacodynamics properties as well as reduced toxicity.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 2 NIH $2,284,577
Project Title: R&D Nanoemulsion Formulation and Ind Enabling Studies of a Novel Center Stem Cell Cytotoxic Agent

Key People / Management

  James Egan -- President and CEO

Company News

There are no news available.